Breast Cancer Risk Biomarkers in Premenopausal Women
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to gather information on how the prescription drug Lovaza™ which
contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer.
This drug is currently approved by the FDA for reducing blood levels of triglycerides.